BJDX: Bluejay Diagnostics, Inc. Stock

by  •  • Comments Off on BJDX: Bluejay Diagnostics, Inc. Stock

SIC 3841 – Surgical and Medical Instruments and Apparatus

Valuation
Market Cap ($M) 1.48
Enterprise Value ($M) -0.73
Book Value ($M) 2.89
Book Value / Share 1.08
Price / Book 0.51
NCAV ($M) 1.25
NCAV / Share 0.46
Price / NCAV 1.19

Profitability (mra)
Return on Invested Capital (ROIC) -3.05
Return on Assets (ROA) -0.91
Return on Equity (ROE) -1.09

Liquidity (mrq)
Quick Ratio 1.82
Current Ratio 1.82

Balance Sheet (mrq) ($M)
Current Assets 3.22
Assets 4.87
Liabilities 1.97
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -10.31
Net Income -9.95
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -8.31
Cash from Investing -0.70
Cash from Financing 1.11

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G Armistice Capital, Llc 9.99
01-03 13G Sabby Management, Llc 9.99 -81.76

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 ☐ TRANSITION REPORT PURSUA
2023-11-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPO
2023-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PU
2023-05-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT P
2023-05-01 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 ☐ TRAN

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-26 36,734 97,980 37.49
2024-04-25 2,634 2,598 101.39
2024-04-24 8,352 646 1,292.88
2024-04-23 6,608 1,765 374.39

(click for more detail)

Similar Companies
BBLG – Bone Biologics Corporation BEAT – HeartBeam, Inc.
BIOL – BIOLASE, Inc. BLAC – Bellevue Life Sciences Acquisition Corp.
BLFS – BioLife Solutions, Inc.


Financial data and stock pages provided by
Fintel.io